Literature DB >> 538442

[Pharmacokinetics of a new cephalosporin, cefoperazone].

A F Allaz, P Dayer, J Fabre, M Rudhardt, L Balant.   

Abstract

Cefoperazone is a semi-synthetic cephalosporin for parenteral use with an extended antibacterial spectrum covering Pseudomonas aeruginosa, Enterobacter cloacae and Serratia marcescens. Its pharmacokinetic properties were studied in 8 healthy subjects after 2 intravenous infusions of 2 g of the drug at a 12-hour interval. The mean peak serum concentrations were 134 +/- 16 microgram/ml and 143 microgram/ml. Cefoperazone was shown to possess a long half-life for a cephalosporin (1.7 hours). In our concentration range the drug is 90% protein bound. The apparent volume of distribution was a mean 11.4 liters and the renal clearance 18 ml/min. The cumulative urinary excretion was small, viz. 23% in 12 hours, indicating that there should be no need to modify the dosage regimen in renal failure. Comparison of in vitro studies with the pharmacokinetic properties show that 2 g cefoperazone given intravenously twice a day should inhibit most sensitive bacteria.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 538442

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  8 in total

1.  A model of cefoperazone tissue penetration: diffusion coefficient and protein binding.

Authors:  A Meulemans
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

Authors:  P J McNamara; K Stoeckel; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Decreased extrarenal clearance of cefoperazone in hepatocellular diseases.

Authors:  B Cochet; J Belaieff; A F Allaz; M Rudhardt; L Balant; J Fabre
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

4.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

5.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 7.  Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; A Carmine; R C Heel; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-12       Impact factor: 9.546

Review 8.  Pharmacokinetics of cefoperazone: a review.

Authors:  W A Craig; A U Gerber
Journal:  Drugs       Date:  1981       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.